Granted Patent
B2
US 12,673,063 · App. 17/920,502 · Granted Jul 7, 2026
Methods and materials for treatment of fibrosis
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are methods for treating and reducing risk of fibrosis, e.g., pulmonary fibrosis, in a subject by administering an inhibitor of RUNX family transcription factor 1 (RUNX1) or core-binding factor subunit beta (CBFβ), e.g., in a subject who has a viral infection.
Claims (4)
1 . A method for treating pulmonary fibrosis in a subject, the method comprising administering an effective amount of an inhibitor of runt-related family transcription factor 1 (RUNX1) selected from Ro24-7429 (7-chloro-N-methyl-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine); Ro5-3335 (7-Chloro-1,3-dihydro-5-(1H-pyrrol-2-yl)-2H-1,4-benzodiazepin-2-one); 7-fluoro-N-methyl-5-(1H-pyrrol-2-yl)-3H-1,4-Benzodiazepin-2-amine; 7-fluoro-1,3-dihydro-5-(1H-pyrrol-2yl)-2H-1,4-benzodiazepin-2-one; NSC140873; MLS000548294; MLS001048862; or NSC156594.
2 . The method of claim 1 , wherein the subject has a viral, bacterial, or fungal infection, or has had a chemical lung injury.
3 . A method for treating pulmonary fibrosis in a subject who has a coronavirus infection, the method comprising administering an effective amount of an inhibitor of runt-related family transcription factor 1 (RUNX1) selected from Ro24-7429 (7-chloro-N-methyl-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine); Ro5-3335 (7-Chloro-1,3-dihydro-5-(1H-pyrrol-2-yl)-2H-1,4-benzodiazepin-2-one); 7-fluoro-N-methyl-5-(1H-pyrrol-2-yl)-3H-1,4-Benzodiazepin-2-amine; 7-fluoro-1,3-dihydro-5-(1H-pyrrol-2yl)-2H-1,4-benzodiazepin-2-one; NSC140873; MLS000548294; MLS001048862; or NSC156594.
4 . The method of claim 3 , wherein the coronavirus infection is infection with SARS or SARS-CoV-2.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 4, 2026
From: THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
To: MASSACHUSETTS EYE AND EAR INFIRMARY
Reel/Frame 074846/0133 →
CONFIRMATORY LICENSE
Recorded May 26, 2023
From: MASS GENERAL BRIGHAM INNOVATION
To: UNITED STATES GOVERNMENT
Reel/Frame 063789/0626 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 20, 2022
From: ARBOLEDA-VELASQUEZ, JOSEPH F.; KIM, LEO A.
To: THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
Reel/Frame 062155/0162 →
Continuity (3)
Provisional Application
63129418
· Dec 22, 2020
Provisional Application
63014194
· Apr 23, 2020
References Cited (333)
US 3405122A
· Berger et al.
· 1968
[cited by applicant]
US 4309404A
· Deneale et al.
· 1982
[cited by applicant]
US 4309406A
· Guley et al.
· 1982
[cited by applicant]
US 4521210A
· Wong
· 1985
[cited by applicant]
US 4556552A
· Porter et al.
· 1985
[cited by applicant]
US 4704295A
· Porter et al.
· 1987
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 4853224A
· Wong
· 1989
[cited by applicant]
US 4997652A
· Wong
· 1991
[cited by applicant]
US 5036101A
· Hsu et al.
· 1991
[cited by applicant]
US 5041438A
· Hsu
· 1991
[cited by applicant]
US 5141735A
· Bellemin et al.
· 1992
[cited by applicant]
US 5164188A
· Wong
· 1992
[cited by applicant]
US 5164376A
· Hsu et al.
· 1992
[cited by applicant]
US 5443505A
· Wong et al.
· 1995
[cited by applicant]
US 5501856A
· Ohtori et al.
· 1996
[cited by applicant]
US 5545806A
· Lonbera et al.
· 1996
[cited by applicant]
US 5545807A
· Surani et al.
· 1996
[cited by applicant]
US 5569825A
· Lonbera et al.
· 1996
[cited by applicant]
US 5582981A
· Toole et al.
· 1996
[cited by applicant]
US 5625126A
· Lonberg et al.
· 1997
[cited by applicant]
US 5633425A
· Lonbera et al.
· 1997
[cited by applicant]
US 5641673A
· Haseloff et al.
· 1997
[cited by applicant]
US 5641750A
· Louis
· 1997
[cited by applicant]
US 5641773A
· Pardee et al.
· 1997
[cited by applicant]
US 5661016A
· Lonbera et al.
· 1997
[cited by applicant]
US 5731005A
· Ottoboni et al.
· 1998
[cited by applicant]
US 5766242A
· Wong et al.
· 1998
[cited by applicant]
US 5824072A
· Wong
· 1998
[cited by applicant]
US 5837226A
· Junaherr et al.
· 1998
[cited by applicant]
US 5869079A
· Wong et al.
· 1999
[cited by applicant]
US 6074661A
· Oleinik et al.
· 2000
[cited by applicant]
US 6331313B1
· Wong et al.
· 2001
[cited by applicant]
US 6369116B1
· Wong et al.
· 2002
[cited by applicant]
US 6699493B2
· Wong
· 2004
[cited by applicant]
US 6719971B1
· Carter et al.
· 2004
[cited by applicant]
US 7354574B2
· Peyman
· 2008
[cited by applicant]
US 8053454B2
· Kearney et al.
· 2011
[cited by applicant]
US 8293210B2
· Huana et al.
· 2012
[cited by applicant]
US 8484010B2
· Tuszynski et al.
· 2013
[cited by applicant]
US 8697359B1
· Zhang
· 2014
[cited by applicant]
US 9023649B2
· Mali et al.
· 2015
[cited by applicant]
US 9074199B1
· Chavez et al.
· 2015
[cited by applicant]
US 9133269B2
· McConnell et al.
· 2015
[cited by applicant]
US 9446048B2
· Liu et al.
· 2016
[cited by applicant]
US 20040229816A1
· Paris et al.
· 2004
[cited by applicant]
US 20060034834A1
· Marasco et al.
· 2006
[cited by applicant]
US 20060264380A1
· Hellstrom et al.
· 2006
[cited by applicant]
US 20070141066A1
· Phillips et al.
· 2007
[cited by applicant]
US 20090203011A1
· Liebenberg et al.
· 2009
[cited by applicant]
US 20090220488A1
· Gardner
· 2009
[cited by applicant]
US 20100233194A1
· Combal et al.
· 2010
[cited by applicant]
US 20130156795A1
· Iavarone et al.
· 2013
[cited by applicant]
US 20140249135A1
· Buraer et al.
· 2014
[cited by applicant]
US 20200103419A1
· Arboleda-Velasquez et al.
· 2020
[cited by applicant]
US 20230190959A1
· Arboleda-Velasquez
· 2023
[cited by applicant]
US 20230310446A1
· Kim et al.
· 2023
[cited by applicant]
WO WO1993011161
· 1993
[cited by applicant]
WO WO2003078662
· 2003
[cited by applicant]
WO WO2007017065
· 2007
[cited by applicant]
WO WO2008130315
· 2008
[cited by applicant]
WO WO2009146456
· 2009
[cited by applicant]
WO WO2009152901
· 2009
[cited by applicant]
WO WO2011163669
· 2011
[cited by applicant]
WO WO2012174419
· 2012
[cited by applicant]
WO WO2015049356
· 2015
[cited by applicant]
WO WO2016025744
· 2016
[cited by applicant]
WO WO2016182904
· 2016
[cited by applicant]
WO WO2017112823
· 2017
[cited by applicant]
WO WO2017117538A1
· 2017
[cited by applicant]
WO WO2018183216
· 2018
[cited by applicant]
WO WO2019040448A1
· 2019
[cited by examiner]
WO WO2019099560
· 2019
[cited by applicant]
WO WO2021062412
· 2021
[cited by applicant]
Cunningham et al. (PNAS, 2012, 109, 36, 14592-14597). (Year: 2012).
[cited by examiner]
Haubrich et al. (J of Infectious Diseases, 1995, 1246-1252). (Year: 1996).
[cited by examiner]
Vanderbilt University, https://news.vumc.org/2024/03/25/vumc-team-finds-potential-treatment-for-kidney-fibrosis/, 2024). (Year: 2024).
[cited by examiner]
Cleveland Clinic, https://my.clevelandclinic.org/health/diseases/10959-pulmonary-fibrosis, 2025 (Year: 2025).
[cited by examiner]
Huang,Signal Transduction and Targeted Therapy, 2023, p. 1-20 (Year: 2023).
[cited by examiner]
Zhang, World J Hepatol Jun. 27, 2023; 15(6): 755-774 (Year: 2023).
[cited by examiner]
MedicalNews (https://www.medicalnewstoday.com/articles/pulmonary-fibrosis#outlook, 2025 ) (Year: 2025).
[cited by examiner]
Partial European Search Report in European Appln. No. 21791849.9, dated Mar. 7, 2024, 14 pages.
[cited by applicant]
Illendula et al., “A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice,” Science, Feb. 2015, 347(6223):779-84.
[cited by applicant]
Office Action in Japanese Appln. No. 2022-564401, mailed on May 20, 2025, 12 pages (with English Translation).
[cited by applicant]
[No Author Listed], “Retinopathy of Prematurity,” American Association for Pediatric Ophthalmology and Strabismus, retrieved from URL<https://aapos.org/glossary/retinopathy-of-prematurity>, available on or before Apr. 2…
[cited by applicant]
Ackermann et al., “Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19,” New England Journal of Medicine, Jul. 2020, 383(2):120-8.
[cited by applicant]
Alder et al., “Diagnostic utility of telomere length testing in a hospital-based setting,” Proceedings of the National Academy of Sciences of the United States of America, Mar. 2018, 115(10):E2358-E2365.
[cited by applicant]
Antonetti et al., “Vascular Endothelial Growth Factor Induces Rapid Phosphorylation of Tight Junction Proteins Occludin and Zonula Occluden 1,” J Biol Chem., Aug. 1999, 274(33):23463-23467.
[cited by applicant]
Arevalo et al., “Tractional Retinal Detachment Following Intravitreal Bevacizumab (Avastin) in Patients With Severe Proliferative Diabetic Retinopathy,” Br. J. Ophthalmol., Feb. 2008, 92(2):213-216.
[cited by applicant]
Barberis et al., “Discovery of N-Substituted 7-Azaindoles as Pan-PIM Kinase Inhibitors—Lead Series Identification—Part II,” Bioorganic & Medicinal Chemistry Letters, Sep. 2017, 27(20):4735-4740.
[cited by applicant]
Bataille et al., “Thiazolidine Derivatives as Potent and Selective Inhibitors of the PIM Kinase Family,” Bioorganic & Medicinal Chemistry, May 2017, 25(9):2657-2665.
[cited by applicant]
Bataller and Brenner, “Liver fibrosis,” J Clin Invest., Feb. 2005, 15(2):209-18.
[cited by applicant]
Beigel et al., “Remdesivir for the Treatment of Covid-19—Final Report,” New England Journal of Medicine, Nov. 2020, 383(19):1813-26, 14 pages.
[cited by applicant]
Bellissimo et al., “Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling,” Blood Advances, Mar. 2020, 4(6):1145-58.
[cited by applicant]
Belser et al., “Ocular tropism of respiratory viruses,” Microbiol Mol Biol Rev., Mar. 2013, 77(1):144-56.
[cited by applicant]
Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, Jan. 1977, 66(1):1-19.
[cited by applicant]
Bergers et al., “Tumorigenesis and the Angiogenic Switch,” Nature Reviews Cancer, Jun. 2003, 3(6):401-410.
[cited by applicant]
Blackwell et al., “Sequence-specific DNA Binding by the c-Myc Protein,” Science, Nov. 1990, 250(4984):1149-1151.
[cited by applicant]
Boerner et al., “Production of Antigen-Specific Human Monoclonal Antibodies from in Vitro-Primed Human Splenocytes,” J. Immunol., Jul. 1991, 147(1):86-95.
[cited by applicant]
Bonniaud et al., “Smad3 Null Mice Develop Airspace Enlargement and Are Resistant to TGF-β-Mediated Pulmonary Fibrosis,” The Journal of Immunology, Aug. 2004, 173(3):2099, 11 pages.
[cited by applicant]
Boyd, “Diabetic Retinopathy Diagnosis,” American Academy of Ophthamology, 2013, retrieved on Sep. 8, 2020, retrieved from URL <https://www.aao.org/eye-health/diseases/diabetic-retinopathy-diagnosis>, 6 pages.
[cited by applicant]
Bravo et al., “The leukemia-associated AML1 (Runx1)-CBFbeta complex functions as a DNA-induced molecular clamp,” Nature Structural Biology, Apr. 2001, 8(4):371-8.
[cited by applicant]
Burns et al., “Hematopoietic Stem Cell Fate Is Established by the Notch-Runx Pathway,” Genes & Development, Oct. 2005, 19(19):2331-2342.
[cited by applicant]
Butko et al., “Complex regulation of HSC emergence by the Notch signaling pathway,” Dev. Biol., Jan. 2016, 409(1):129-138.
[cited by applicant]
Castilla et al., “Failure of Embryonic Hematopoiesis and Lethal Hemorrhages in Mouse Embryos Heterozygous for a Knocked-In Leukemia Gene CBFB-MYH11,” Cell, Nov. 1996, 87(4):687- 696.
[cited by applicant]
Chang et al., “PIM Kinase Inhibitors Downregulate STAT3Tyr705 Phosphorylation,” Mol Cancer Ther., Sep. 2010, 9(9):2478-2487.
[cited by applicant]
Cheema et al., “Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19),” Can J Ophthalmol., Aug. 2020, 55(4):e125-e129.
[cited by applicant]
Cheloufi et al., “A Dicer-independent miRNA biogenesis pathway that requires Ago catalysis,” Nature, Jun. 2010, 465(7298):584-589.
[cited by applicant]
Chen et al., “Intracellular Antibodies as a New Class of Therapeutic Molecules for Gene Therapy,” Human Gene Therapy, 1994, 5(5):595-601.
[cited by applicant]
Chen et al., “Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease,” Br J Ophthalmol., Jun. 2020, 104(6):748-751.
[cited by applicant]
Chen et al., “Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter,” Nature, Feb. 2009, 457(7231):887-891.
[cited by applicant]
Chothia et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” J. Mol. Biol., Aug. 1987, 196(4):901-917.
[cited by applicant]
Chothia et al., “Conformations of immunoglobulin hypervariable regions,” Nature, Dec. 1989, 342:877-883.
[cited by applicant]
Chung et al., “Developmental and Pathological Angiogenesis,” Annu. Rev. Cell Dev. Biol., Nov. 2011, 27:563-584.
[cited by applicant]
Cole, “Monoclonal Antibodies,” Can. Fam. Physician, 1987, 33:369-372.
[cited by applicant]
Colyer et al., “Perforating globe injuries during operation Iraqi Freedom,” Ophthalmology, 2008, 115:2087-2093.
[cited by applicant]
Connor et al., “Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis,” Nat Protoc., Oct. 2009, 4(11):1565-1573.
[cited by applicant]
Cunningham et al., “Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction,” PNAS, Sep. 2012, 109(36):14592-14597.
[cited by applicant]
Daxer, “The Fractal Geometry of Proliferative Diabetic Retinopathy: Implications for the Diagnosis and the Process of Retinal Vasculogenesis,” Current Eye Research, Dec. 1993, 12(12):1103-1109.
[cited by applicant]
Delgado-Tirado et al., “Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy,” Scientific Reports, Nov. 2020, 10(1):20554, 15 pages.
[cited by applicant]
Diabetes Control and Complications Trial Research Group, “The Relationship of Glycemic Exposure (HbA1c) to the Risk of Development and Progression of Retinopathy in the Diabetes Control and Complications Trial,” Diabete…
[cited by applicant]
Dua et al., “The ocular surface as part of the mucosal immune system: conjunctival mucosa-specific lymphocytes in ocular surface pathology,” Eye (Lond.), 1995, 9(Pt 3):261-7.
[cited by applicant]
Dubois et al., “Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme,” Am J Pathol., Jan. 2001, 158(1):305-16.
[cited by applicant]
Eapen et al., “Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration?,” European Respiratory Journal, Oct. 2020, 56(4):2003167, 3 pages.
[cited by applicant]
Edgar et al., “Gene Expression Omnibus: NCBI gene expression and hybridization array data repository,” Nucleic Acids Research, Jan. 2002, 30(1):207-210.
[cited by applicant]
Elbashir et al., “Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate,” The EMBO Journal, Dec. 2001, 20(23):6877-6888.
[cited by applicant]
Eliott et al., “Smoking is a risk factor for proliferative vitreoretinopathy after traumatic retinal detachment,” Retina, 2017, 37(7):1229-1235.
[cited by applicant]
Espinoza et al., “Notch Inhibitors for Cancer Treatment,” Pharmacol Ther., Aug. 2013, 139(2):95-110.
[cited by applicant]
Eye.Hms.Harvard.edu [online], “Harvard Medical School Dept. of Ophthalmology Home/News,” Apr. 2017, retrieved on Dec. 10, 2021, retrieved from URL<https://eye.hms.harvard.edu/news/researchers-identify-new-target-abnorma…
[cited by applicant]
Fehniger et al., “Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13,” Blood, 2009, 113(5):1002-1005.
[cited by applicant]
Fire et al., “Potent and Specific Genetic Interference by Double-Stranded RNA in Caenorhabditis Elegans,” Nature, 1998, 391:806-810.
[cited by applicant]
Fishwild et al., “High-Avidity Human IgG Kappa Monoclonal Antibodies from a Novel Strain of Minilocus Transgenic Mice,” Nature Biotechnology, Aug. 1996, 14(7):845-851.
[cited by applicant]
Frangogiannis, “Fibroblast-Extracellular Matrix Interactions in Tissue Fibrosis,” HHS Public Access Author Manuscript, doi:10.1007/s40139-016-0099-1, published online Feb. 5, 2016, 14 pages; Published in final edited fo…
[cited by applicant]
Fràter-Schröder et al., “Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo,” Proc Natl Acad Sci USA, Aug. 1987, 84(15):5277-81.
[cited by applicant]
Friedlander, “Fibrosis and diseases of the eye,” J Clin Invest., 2007, 117(3):576-586.
[cited by applicant]
Geback et al., “TScratch: A novel and simple software tool for automated analysis of monolayer wound healing assays,” Biotechniques, Apr. 2009, 46(4):265-274.
[cited by applicant]
GenBank Accession No. AAI41856.1, “Pim-3 oncogene [
[cited by applicant]
GenBank Accession No. AB114795.1, “
[cited by applicant]
GenBank Accession No. AK292005.1, “
[cited by applicant]
GenBank Accession No. BAD42438.1, “serine/threonine kinase Pim-3 [
[cited by applicant]
GenBank Accession No. BAF84694.1, “Unnamed protein product [
[cited by applicant]
GenBank Accession No. BC141855.1, “
[cited by applicant]
GenBank Accession No. NM_000598.4, “
[cited by applicant]
GenBank Accession No. NM_001001852.4, “
[cited by applicant]
GenBank Accession No. NM_001001890.2, “
[cited by applicant]
GenBank Accession No. NM_001013398.1, “
[cited by applicant]
GenBank Accession No. NM_001122607.2, “
[cited by applicant]
GenBank Accession No. NM_001754.4, “
[cited by applicant]
GenBank Accession No. NP_000589.2, “Insulin-like growth factor-binding protein 3 isoform b precursor [
[cited by applicant]
GenBank Accession No. NP_001013416.1, “Insulin-like growth factor-binding protein 3 isoform a precursor [
[cited by applicant]
GenBank Accession No. XM_005261068.3, “Predicted:
[cited by applicant]
GenBank Accession No. XM_005261069.4, “Predicted:
[cited by applicant]
GenBank Accession No. XM_011529766.2, “Predicted:
[cited by applicant]
GenBank Accession No. XM_011529768.2, “Predicted:
[cited by applicant]
GenBank Accession No. XM_011529770.2, “Predicted:
[cited by applicant]
GenBank Accession No. XM_017028487.1, “Predicted:
[cited by applicant]
GenBank Accession No. XR 937576.2, “PREDICTED: Homo sapiens RUNX family transcription factor 1 (RUNX1), transcript variant X7, misc_RNA”, May 28, 2020, 3 pages.
[cited by applicant]
George et al., “Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy,” The Lancet Respiratory Medicine, Aug. 2020, 8(8):807-15.
[cited by applicant]
ghr.nlm.nih.gov [online], “Age-related macular degeneration,” Aug. 2016, retrieved from URL <https://ghr.nlm.nih.gov/condition/age-related-macular-degeneration>, 8 pages.
[cited by applicant]
Giani et al., “In Vivo Evaluation of Laser-Induced Choroidal Neovascularization Using Spectral- Domain Optical Coherence Tomography,” Investigative Ophthalmology & Visual Science, 2011, 52(6):3880-3887.
[cited by applicant]
Glinsky, “Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-…
[cited by applicant]
Graney and Lee, “Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives,” Patient Relat Outcome Meas., 2018, 9:321-8.
[cited by applicant]
Hakeem et al., “Retinopathy of Prematurity: A Study of Prevalence and Risk Factors,” Middle East African Journal of Ophthalmology, 2012, 19(3):289-294.
[cited by applicant]
Harris et al., “Glucose Metabolism Impacts the Spatiotemporal Onset and Magnitude of HSC Induction in Vivo,” Blood, Mar. 2013, 121(13):2483-2493.
[cited by applicant]
Haubrich et al., “A Randomized Trial of the Activity and Safety of Ro 24-7429 (Tat Antagonist) Versus Nucleoside for Human Immunodeficiency Virus Infection,” The Journal of Infectious Diseases, Nov. 1995, 172(5): 1246-1…
[cited by applicant]
Heckl et al., “Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing,” Nat. Biotechnol., 2014, 32(9):941-946, 14 pages.
[cited by applicant]
Hendren et al., “Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome,” Circulation, Apr. 2020, 141(23):1903-1914, 19 pages.
[cited by applicant]
Holliger et al., “‘Diabodies’: Small Bivalent and Bispecific Antibody Fragments,” Proceedings of the National Academy of Sciences of the United States of America, Jul. 1993, 90(14):6444-6448.
[cited by applicant]
Hong et al., “Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition,” Oncotarget, Mar. 2017, 8(11):17610-17627.
[cited by applicant]
Hoogenboom et al., “By-Passing immunisation: Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in Vitro,” Journal of Molecular Biology, Sep. 1992, 227(2):381-388.
[cited by applicant]
Hoyt et al., “Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice,” J Pharmacol Exp Ther., Aug. 1988, 246(2):765-71.
[cited by applicant]
Hsu et al., “Combined Tractional and Rhegmatogenous Retinal Detachment in Proliferative Diabetic Retinopathy in the Anti-VEGF Era”, Journal of Ophthalmology, Jun. 2014, Article ID 917375, 2014(7):11 pages.
[cited by applicant]
Hsu et al., “Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro,” Proc Natl Acad Sci USA, Jun. 1993, 90(14):6395-9.
[cited by applicant]
Huang et al., “Bioinformatics Enrichment Tools: Paths Toward the Comprehensive Functional Analysis of Large Gene Lists,” Nucleic Acids Research, Jan. 2009, 37(1):1-13.
[cited by applicant]
Huertas et al., “Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?,” European Respiratory Journal, Jul. 2020, 56(1):2001634, 5 pages.
[cited by applicant]
Hutchinson et al., “Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review,” European Respiratory Journal, Sep. 2015, 46(3):795-806.
[cited by applicant]
Illendula et al., “Small Molecule Inhibitor of CBF˜-RUNX Binding for RUNX Transcription Factor Driven Cancers,” EBioMedicine, Nov. 2017, 8:117-131.
[cited by applicant]
Imanirad et al., “HIF1α is a Regulator of Hematopoietic Progenitor and Stem Cell Development in Hypoxic Sites of the Mouse Embryo,” Stem Cell Res., Jan. 2014, 12(1):24-35.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2017/061620, dated May 21, 2019, 17 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2018/061110, dated May 28, 2020, 12 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2021/027798, mailed on Nov. 3, 2022, 9 pages.
[cited by applicant]
International Search Report and the Written Opinion in International Appln. No. PCT/US2018/061110, dated Mar. 25, 2019, 17 pages.
[cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2021/027798, dated Sep. 28, 2021, 13 pages.
[cited by applicant]
International Search Report in International Appln. No. PCT/US2017/061620, dated Mar. 19, 2018, 24 pages.
[cited by applicant]
Ishikawa et al., “Microarray Analysis of Gene Expression in Fibrovascular Membranes Excised From Patients With Proliferative Diabetic Retinopathy,” Investigative Ophthalmology & Visual Science, Feb. 2015, 56(2):932-946.
[cited by applicant]
Ito et al., “RUNX Transcription Factors as Key Targets of TGF-beta Superfamily Signaling,” Current Opinion in Genetics and Development, Feb. 2003, 13(1):43-47.
[cited by applicant]
Iwatsuki et al., “Runx1 Promotes Angiogenesis by Downregulation of Insulin-Like Growth Factor-Binding Protein-3”, Oncogene, Feb. 2005, 24(7):1129-1137.
[cited by applicant]
Ji et al., “Inflammatory regulatory network mediated by the joint action of NF-kB, STAT3, and AP-1 factors is involved in many human cancers,” Proceedings of the National Academy of Sciences, May 2019, 116(19):9453-9462.
[cited by applicant]
Jo et al., “Animal Models of Diabetic Retinopathy: Doors to Investigate Pathogenesis and Potential Therapeutics,” Journal of Biomedical Science, 2013, 20:38, 13 pages.
[cited by applicant]
Jones et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse,” Nature, May 1986, 321(6069):522-525.
[cited by applicant]
Joyce, “Amplification, Mutation and Selection of Catalytic RNA,” Gene, Oct. 1989, 82(1):83-87.
[cited by applicant]
Kalev-Zylinska et al., “Runx1 is Required for Zebrafish Blood and Vessel Development and Expression of a Human RUNX1-CBF2T1 Transgene Advances a Model for Studies of Leukemogenesis,” Development, 2002, 129(8):2015-2030.
[cited by applicant]
Kategaya et al., “USP7 Small-Molecule Inhibitors Interfere With Ubiquitin Binding,” Nature, Oct. 2017, 550(7677):534-538, 33 pages.
[cited by applicant]
Kim et al., “A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis,” The American Journal of Pathology, 2012, 181(2):376-379.
[cited by applicant]
Kim et al., “Characterization of Cells from Patient-Derived Fibrovascular Membranes in Proliferative Diabetic Retinopathy,” Molecular Vision, Jun. 2015, 21:673-687.
[cited by applicant]
Kim et al., “Inhibition of Runx1 by the Ro5-3335 benzodiazepine derivative reduces aberrant retinal angiogenesis,” Abstract, Presented at Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)…
[cited by applicant]
Kim et al., “Pim-1 Kinase Phosphorylates and Stabilizes RUNX3 and Alters Its Subcellular Localization,” Journal of Cellular Biochemistry, Nov. 2008, 105(4):1048-1055.
[cited by applicant]
Kim et al., “RUNX1 is essential for mesenchymal stem cell proliferation and myofibroblast differentiation,” Proc Natl Acad Sci USA, Nov. 2014, 111(46):16389-94.
[cited by applicant]
Köhler et al., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,” Nature, Aug. 1975, 256(5517):495-497.
[cited by applicant]
Kozlowski et al., “A Human Melanoma Line Heterogeneous With Respect to Metastatic Capacity in Athymic Nude Mice,” Journal of the National Cancer Institute, Apr. 1984, 72(4):913-917.
[cited by applicant]
Kuiper et al., “The Angio-Fibrotic Switch of VEGF and CTGF in Proliferative Diabetic Retinopathy,” PLoS ONE, Jul. 2008, 3(7):e2675, 7 pages.
[cited by applicant]
Lam et al., “Identification of RUNX1 as a Mediator of Aberrant Retinal Angiogenesis,” Diabetes, 2017, 66:1950-1956.
[cited by applicant]
Lederer et al., “Idiopathic Pulmonary Fibrosis,” New England Journal of Medicine, May 2018, 378(19):1811-23.
[cited by applicant]
Lee et al., “TGF-β regulates cell fate during epithelial-mesenchymal transition by upregulating survivin,” Cell Death & Disease, Jul. 2013, 4(7):e714, 10 pages.
[cited by applicant]
Li et al., “RUNX1 promotes tumour metastasis by activating the WNT/beta-catenin signalling pathway and EMT in colorectal cancer,” J Exp Clin Cancer Res, Aug. 2019, 38(1):334, 13 pages.
[cited by applicant]
Liang et al., “In Vitro Scratch Assay: A Convenient and Inexpensive Method for Analysis of Cell Migration in Vitro,” Nature Protocols, Mar. 2007, 2(2):329-333.
[cited by applicant]
Liberati et al., “Smads bind directly to the Jun family of AP-1 transcription factors,” Proc Natl Acad Sci USA, Apr. 1999, 96(9):4844-9.
[cited by applicant]
Lichtinger et al., “Chromatin Regulation by RUNX1,” Blood Cells, Molecules and Diseases, Apr. 2010, 44(4):287-290.
[cited by applicant]
Lie-A-Ling et al., “RUNX1 Positively Regulates a Cell Adhesion and Migration Program in Murine Hemogenic Endothelium Prior to Blood Emergence,” Blood, Sep. 2014, 124(11):e11-e20.
[cited by applicant]
Lin et al., “LncRNA Hoxaas3 promotes lung fibroblast activation and fibrosis by targeting miR-450b-5p to regulate Runx1,” Cell Death & Disease, Aug. 2020, 11(8):706, 14 pages.
[cited by applicant]
Liu et al., “Conjunctiva is not a preferred gateway of entry for SARS-CoV-2 to infect respiratory tract,” Med Virol., Sep. 2020, 92(9):1410-1412.
[cited by applicant]
Lofqvist et al., “IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth,” PNAS, 2007, 104(25):10589-10594.
[cited by applicant]
Lonberg et al., “Antigen-Specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications,” Nature, Apr. 1994, 368:856-859.
[cited by applicant]
Lonberg et al., “Human Antibodies from Transgenic Mice,” Intern. Rev. Immunol., 1995, 13(1):65-93.
[cited by applicant]
Lucas et al., “Abstract: Formation of abdominal adhesions is inhibited by antibodies to transforming growth factor-beta 1,” J Surg Res., Oct. 1996, 65(2):135-8, 4 pages.
[cited by applicant]
Ludwig, “The Use of Mucoadhesive Polymers in Ocular Drug Delivery,” Advanced Drug Delivery Reviews, 2005, 57(11):1595-1639.
[cited by applicant]
Maher, “PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery,” European Respiratory Review, Jun. 2013, 22(128):148-52.
[cited by applicant]
Malaviya et al., “Anti-TNFα therapy in inflammatory lung diseases,” HHS Public Access Author Manuscript, doi:10.1016/j.pharmthera.2017.06.008, published online Nov. 4, 2017, 23 pages; Published in final edited form as: …
[cited by applicant]
Malaviya et al., “Attenuation of Nitrogen Mustard-Induced Pulmonary Injury and Fibrosis by Anti-Tumor Necrosis Factor-a Antibody,” Toxicological Sciences, Nov. 2015, 148(1):71-88.
[cited by applicant]
Marks et al., “By-Passing Immunization: Human Antibodies from V-Gene Libraries Displayed on Phage,” J. Mol. Biol., Dec. 1991, 222(3):581-597.
[cited by applicant]
Martin et al., “TGF-β1 and radiation fibrosis: a master switch and a specific therapeutic target?,” Int J Radiat Oncol Biol Phys., May 2000, 47(2):277-90.
[cited by applicant]
Martines et al., “Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Corona virus Disease, United States,” Emerg Infect Dis., Sep. 2020, 26(9):2005-15.
[cited by applicant]
Martinez-Hoyer et al., “RUNX1 Loss of Function Drives Resistance to Lenalidomide in Del(5Q) Myelodysplastic Syndrome Patients,” Leukemia Research, 2017, 1(55):S43-S44.
[cited by applicant]
Masoumpour et al., “Current and Future Techniques in Wound Healing Modulation after Glaucoma Filtering Surgeries,” Open Ophthalmol J., 2016, 10:68-85.
[cited by applicant]
mayoclinic.org [online], “Diabetic Retinopathy,” Mar. 2015, via Internet archive: Wayback Machine URL <http://web.archive.org/web/20180308085607/https://www.mayoclinic.org/diseases-conditions/diabetic-retinopathy/diagno…
[cited by applicant]
mayoclinic.org [online], “Dry Macular Degeneration,” 2015, retrieved from URL <https://www.mayoclinic.org/diseasesconditions/drymaculardegeneration/diagnosis-treatment/drc-20350381>, 5 pages.
[cited by applicant]
mayoclinic.org [online], “Wet Macular Degeneration,” 2015, retrieved from URL <https://www.mayoclinic.org/diseasesconditions/wet-macular-degeneration/diagnosis-treatment/drc-20351113>, 6 pages.
[cited by applicant]
McAuley et al., “Vitreous Biomarkers in Diabetic Retinopathy: A Systematic Review and Meta-Analysis,” Journal of Diabetic Complications, 2014, 28(3):419-425.
[cited by applicant]
McLeod et al., “From Blood Islands to Blood Vessels: Morphologic Observations and Expression of Key Molecules during Hyaloid Vascular System Development,” Investigative Ophthalmology & Visual Science, Dec. 2012, 53(13):…
[cited by applicant]
Medlineplus.gov [online], “Retinal vein occlusion,” Available on or before Mar. 6, 2018, retrieved Feb. 22, 2019, retrieved from URL <https://medlineplus.gov/ency/article/007330.htm>, 4 pages.
[cited by applicant]
Michaud et al., “Integrative Analysis of RUNX1 Downstream Pathways and Target Genes,” BMC Genomics, Jul. 2008, 9:363, 17 pages.
[cited by applicant]
Morrison, “Success in Specification,” Nature, Apr. 1994, 368:812-813.
[cited by applicant]
Moshfeghi et al., “Retinal Capillary Angioma,” American Academy of Ophthalmology, Oct. 2013, 7 pages.
[cited by applicant]
Mukhopadhyay et al., “Role of TNFα in pulmonary pathophysiology,” Respiratory Research, 2006, 7(1):125, 9 pages.
[cited by applicant]
my.clevelandclinic.org [online], “Retinal Vein Occlusion (RVO),” 2015, retrieved from URL <https://my.clevelandclinic.org/health/diseases/14206-retinal-vein-occlusion-rvo>, 4 pages.
[cited by applicant]
Nakano et al., “Design and Synthesis of an in Vivo-Efficacious PIM3 Kinase Inhibitor as a Candidate Anti-Pancreatic Cancer Agent,” Bioorganic & Medicinal Chemistry Letters, Dec. 2015, 25(24):5687-5693.
[cited by applicant]
Namba et al., “Indispensable Role of the Transcription Factor PEBP2/CBF in Angiogenic Activity of a Murine Endothelial Cell MSS31,” Oncogene, Jan. 2000, 19(1):106-114.
[cited by applicant]
nei.nih.gov [online], “Facts About Retinopathy of Prematurity (ROP),” National Eye Institute, available on or before Jun. 2014, retrieved on Feb. 22, 2019, retrieved from URL <https://nei.nih.gov/health/rop/rop>, 3 page…
[cited by applicant]
Neuberger, “Generating High-Avidity Human Mabs in Mice,” Nature Biotechnology, Jul. 1996, 14(7):826, 1 page.
[cited by applicant]
Nicholls et al., “An Improved Method for Generating Single-Chain Antibodies From Hybridomas,” Journal of Immunological Methods, Sep. 1993, 165(1):81-91.
[cited by applicant]
O'Hare et al., “Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators,” The American Journal of Pathology, Jul…
[cited by applicant]
Ojo et al., “Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies,” Pulmonary Medicine, Aug. 2020, 2020:6175964, 10 pages.
[cited by applicant]
Pandya et al., “Neovascular Glaucoma,” Medscape, available on or before Oct. 2016, retrieved from URL <https://emedicine.medscape.com/article/1205736-overview#a6>, 15 pages.
[cited by applicant]
Pashaei et al., “Immunotherapy for SARS-CoV-2: potential opportunities,” Expert Opin Biol Ther., Oct. 2020, 20(10):1111-5.
[cited by applicant]
Pettus et al., “Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors,” J. Med. Chem., Jun. 2016, 59(13):6407-6430.
[cited by applicant]
Pluckthun, “Antibodies from
[cited by applicant]
Polak et al., “A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression,” Mod Pathol., Nov. 2020, 33(11):2128-38.
[cited by applicant]
Pratt et al., “Abstract 1010: Identification of evolutionarily conserved transcription response elements associated with regulation of cadherin expression in retinal pigment epithelial cells,” Molecular Biology of the C…
[cited by applicant]
Presta, “Antibody Engineering,” Current Opinion in Structural Biology, 1992, 2(4):593-596.
[cited by applicant]
Rakoczy et al., “Characterization of a Mouse Model of Hyperglycemia and Retinal Neovascularization,” The American Journal of Pathology, Nov. 2010, 177(5):2659-2670.
[cited by applicant]
Ran et al., “γ-Secretase Inhibitors in Cancer Clinical Trials are Pharmacologically and Functionally Distinct,” EMBO Molecular Medicine, Jul. 2017, 9(7):950-966.
[cited by applicant]
Riddell et al., “RUNX1: an emerging therapeutic target for cardiovascular disease,” Cardiovasc Res., Mar. 2020, 116(8):1410-1423.
[cited by applicant]
Riechmann et al., “Reshaping Human Antibodies for Therapy,” Nature, Mar. 1988, 332:323-327.
[cited by applicant]
Sainson et al., “TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype,” Blood, May 2008, 111(10):4997-5007.
[cited by applicant]
Saint-Geniez et al., “Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Muller Cells and Photoreceptors,” PLoS ONE, Nov. 2008, 3(11):e3554, 13 pages.
[cited by applicant]
Sang et al., “Is Blockade of Vascular Endothelial Growth Factor Beneficial for all Types of Diabetic Retinopathy?” Diabetologia, Jul. 2008, 51(9): 1570-1573.
[cited by applicant]
Schaefer et al., “In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19,” Modern Pathology, Jun. 2020, 33(11):2104-14.
[cited by applicant]
Scholle, “Ocular Ischemic Syndrome,” Medscape, 2019, retrieved Sep. 8, 2020, retrieved from URL <https://emedicine.medscape.com/article/1201678-overview>, 3 pages.
[cited by applicant]
Selman et al., “Idiopathic pulmonary fibrosis: an epithelial fibroblastic cross-talk disorder,” Respir Res., 2002, 3(1):3, 8 pages.
[cited by applicant]
Shah et al., “Alk5/Runx1 signaling mediated by extracellular vesicles promotes vascular repair in acute respiratory distress syndrome,” Clin Transl Med, Jun. 2018, 7(1):19, 18 pages.
[cited by applicant]
Shaki-Loewenstein et al., “A universal strategy for stable intracellular antibodies”, Journal of Immunological Methods, Aug. 2005, 303(1-2):19-39.
[cited by applicant]
Shao et al., “Choroid Sprouting Assay: An Ex Vivo Model of Microvascular Angiogenesis, ” PLoS ONE, Jul. 2013, 8(7):e69552, 11 pages.
[cited by applicant]
Shazly et al., “Neovascular Glaucoma: Etiology, Diagnosis and Prognosis,” Seminars in Ophthalmology, Mar. 2009, 24(2):113-121.
[cited by applicant]
Sinha and Ware, “Selective tumour necrosis factor receptor-1 inhibition in acute lung injury: a new hope or a false dawn?,” Thorax, Aug. 2018, 73(8):699-701.
[cited by applicant]
Smith et al., “Oxygen-Induced Retinopathy in the Mouse,” Invest Ophthalmol Vis Sci, Jan. 1994, 35(1):101-111.
[cited by applicant]
Sohn et al., “Angiofibrotic Response to Vascular Endothelial Growth Factor Inhibition in Diabetic Retinal Detachment,” Arch Ophthalmol, Sep. 2012, 130(9):1127-1134.
[cited by applicant]
Strongman et al., “Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK,” Adv Ther., May 2018, 35(5):724-36.
[cited by applicant]
Sui et al., “oPOSSUM: Identification of Over-represented Transcription Factor Binding Sites in Co-Expressed Genes,” Nucleic Acids Research, 2005, 33(10):3154-3164.
[cited by applicant]
Tang et al., “Runt-Related Transcription Factor 1 Regulates LPS-Induced Acute Lung Injury via NF-κB Signaling,” Am J Respir Cell Mol Biol., 2017, 57(2):174-83.
[cited by applicant]
Tashiro et al., “Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis,” Frontiers in Medicine, Jul. 2017, 4:118, 11 pages.
[cited by applicant]
Terelak-Borys et al., “Ocular Ischemic Syndrome—A Systematic Review,” Med Sci Monit, Aug. 2012, 18(8):RA138-RA144.
[cited by applicant]
The RECOVERY Collaborative Group, “Dexamethasone in Hospitalized Patients with Covid-19—Preliminary Report,” New England Journal of Medicine, Feb. 2021, 384(8):693-704, 11 pages.
[cited by applicant]
Thomas, “Furin at the cutting edge: from protein traffic to embryogenesis and disease,” HHS Public Access Author Manuscript, doi: 10.1038/nrm934, published online 2002, 32 pages; Published in final edited form as Nat Re…
[cited by applicant]
Tober et al., “Taking the leap: Runx1 in the formation of blood from endothelium,” Current Topics in Developmental Biology, Feb. 2016, 118:113-162.
[cited by applicant]
Trapnell et al., “TopHat: Discovering Splice Junctions with RNA-Seq,” Bioinformatics, Apr. 2009, 25(9):1105-1111.
[cited by applicant]
Tuerk et al., “Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase,” Science, Aug. 1990, 249(4968):505-510.
[cited by applicant]
Turell et al., “Vascular Tumors of the Retina and Choroid: Diagnosis and Treatment,” Middle East Afr J Ophthalmol., 2010, 17(3):191-200.
[cited by applicant]
Ulrich et al. “CD147 as a Target for COVID-19 Treatment: Suggested Effects 2, 4-6, 19, 21-23 of Azithromycin and Stem Cell Engagement,” Stem Cell Reviews and Reports, Apr. 2020, 16:434-440, 7 pages.
[cited by applicant]
UniProt Accession No. P17936, “Insulin-like growth factor-binding protein 3,” Nov. 1, 1990, 8 pages.
[cited by applicant]
UniProt Accession No. Q01196-10, “Runt-related transcription factor 1,” Apr. 1, 1993, 1 page.
[cited by applicant]
UniProt Accession No. Q01196-11, “RUNX1_Human Isoform AML-1L of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page.
[cited by applicant]
UniProt Accession No. Q01196-2, “RUNX1_Human Isoform AML-1A of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page.
[cited by applicant]
UniProt Accession No. Q01196-3, “RUNX1_Human Isoform AML-1C of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page.
[cited by applicant]
UniProt Accession No. Q01196-4, “RUNX1_Human Isoform AML-1E of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page.
[cited by applicant]
UniProt Accession No. Q01196-5, “RUNX1_Human Isoform AML-1FA of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page.
[cited by applicant]
UniProt Accession No. Q01196-6, “RUNX1_Human Isoform AML-1FB of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page.
[cited by applicant]
UniProt Accession No. Q01196-7, “RUNX1_Human Isoform AML-1FC of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page.
[cited by applicant]
UniProt Accession No. Q01196-8, “RUNX1_Human Isoform AML-1G of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page.
[cited by applicant]
UniProt Accession No. Q01196-9, “RUNX1_Human Isoform AML-1H of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page.
[cited by applicant]
UniProt Accession No. Q86V86, “Serine/threonine-protein kinase pim-3,” Nov. 21, 2003, 6 pages.
[cited by applicant]
Van Geest et al., “A Shift in the Balance of Vascular Endothelial Growth Factor and Connective Tissue Growth Factor by Bevacizumab Causes the Angiofibrotic Switch in Proliferative Diabetic Retinopathy,” Br J Ophthalmol,…
[cited by applicant]
Vancheri et al., “Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial,” Am J Respir Crit Care Med., Feb. 2018, 197(3):356-63.
[cited by applicant]
Verhoeyen et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity,” Science, Mar. 1988, 239(4847):1534-1536.
[cited by applicant]
Wang et al. “Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor With Optimized Bioavailability,” J. Med. Chem., Apr. 2017, 60(10):4458-4473.
[cited by applicant]
Whitmore et al., “TNF-α signaling regulates RUNX1 function in endothelial cells,” The FASEB Joumal, Feb. 2021, 35(2):e21155, 17 pages.
[cited by applicant]
Wu et al., “Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China,” JAMA Ophthalmol., May 2020, 138(5):575-578.
[cited by applicant]
Xie et al., “Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary Fibrosis,” Cell Rep., Mar. 2018, 22(13):3625-40.
[cited by applicant]
Yadav et al., “Tumour Angiogenesis and Angiogenic Inhibitors: A Review,” J Clin Diagn Res., Jun. 2015, 9(6):XE01-XE05.
[cited by applicant]
Yan et al., “Feedback regulation of TGF-β signaling,” Acta Biochimica et Biophysica Sinica, Jan. 2018, 50(1):37-50.
[cited by applicant]
Yang et al., “Mechanisms of epithelial-mesenchymal transition in proliferative vitreoretinopathy,” Discov Med., Oct. 2015, 20(110):207-217, 21 pages.
[cited by applicant]
Yoshida et al., “Gene expression profile of fibrovascular membranes from patients with proliferative diabetic retinopathy,” Br J Ophthalmol., 2010, 94(6):795-801.
[cited by applicant]
Yuan et al., “Notch Signaling: An Emerging Therapeutic Target for Cancer Treatment,” Cancer Letters, Dec. 2015, 369(1):20-27.
[cited by applicant]
Yue et al., “TGF-β: Titan of Lung Fibrogenesis,” HHS Public Access Author Manuscript, doi: 10.2174/10067, Oct. 2013, 20 pages; Published in final edited form as: Curr Enzym Inhib., Jul. 2010, 6(2):10.2174/10067.
[cited by applicant]
Yzaguirre et al., “The Role of Runx1 in Embryonic Blood Cell Formation,” RUNX Proteins in Development and Cancer, Singapore: Springer Singapore, Groner et al. (eds.), 2017, pp. 47-64.
[cited by applicant]
Zapata et al., “Engineering Linear F(ab′)2 Fragments for Efficient Production in
[cited by applicant]
Zhou et al., “Runt-Related Transcription Factor 1 (RUNX1) Promotes TGF-f3-Induced Renal Tubular Epithelial-to-Mesenchymal Transition (EMT) and Renal Fibrosis through the PI3K Subunit p1108,” EBioMedicine, May 2018, 31:2…
[cited by applicant]
Zhou et al., “RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation,” Leukemia, 2019, 33:2006-2021.
[cited by applicant]
Extended European Search Report in European Appln. No. 21791849.9, dated May 28, 2024, 12 pages.
[cited by applicant]
Office Action in European Appln. No. 21791849.9, mailed on Jun. 13, 2025, 6 pages.
[cited by applicant]
U.S. Appl. No. 62/906,241, filed Sep. 26, 2019, Tata et al.
[cited by applicant]
U.S. Appl. No. 62/975,294, filed Feb. 12, 2020, Tata et al.
[cited by applicant]
Trujillo et al., “Angiogenesis in acute myeloid leukemia and opportunities for novel therapies,” Journal of Oncology, 2012; 2012(1):128608, 9 pages.
[cited by applicant]
Kaelin “Use and abuse of RNAi to study mammalian gene function,” Science, Jul. 2012, 337(6093):421-422, 4 pages (Author Manuscript).
[cited by applicant]
Office Action in Chinese Appln. No. 202180044451.3, mailed on Jan. 4, 2026, 16 pages (with English translation).
[cited by applicant]
Third Party Opposition in European Appln. No. 21791849.9, mailed on Dec. 15, 2025, 10 pages.
[cited by applicant]
Office Action in Japanese Appln. No. 2022-564401, mailed on Jan. 6, 2026, 6 pages (with English Translation).
[cited by applicant]
Weiss et al., “Recognizing and exploiting differences between RNAi and small-molecule inhibitors,” Nature Chemical Biology, Dec. 2007, 3(12):739-744, 12 pages (Author Manuscript).
[cited by applicant]